“THE ROLE OF STATIN THERAPY IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND ATHEROSCLEROSIS: A COMPREHENSIVE REVIEW”

Abstract

Non-alcoholic fatty liver disease has emerged as a major global public health concern, affecting approximately one-third of the adult population worldwide. Increasing evidence indicates that NAFLD is not only a liver-specific condition but also a multisystem disease closely linked to Atherosclerosis and cardiovascular morbidity. Cardiovascular disease remains the leading cause of mortality among patients with NAFLD. This review aims to evaluate the role of statin therapy in patients with NAFLD and concomitant atherosclerosis, focusing on its efficacy, safety, and impact on cardiovascular outcomes. A narrative review of current literature was conducted, including observational studies, randomized clinical trials, and international guideline recommendations addressing statin use in NAFLD and cardiovascular disease. Accumulating data suggest that statins significantly reduce cardiovascular risk in patients with NAFLD by improving lipid profiles, stabilizing atherosclerotic plaques, and exerting anti-inflammatory effects. Importantly, statins have been shown to be safe in most patients with NAFLD, with no increased risk of clinically significant hepatotoxicity. Emerging evidence also indicates potential beneficial effects on liver enzymes and histological parameters. Statin therapy plays a pivotal role in the management of patients with NAFLD and atherosclerosis, offering dual benefits by reducing cardiovascular risk without adversely affecting liver function. Despite strong evidence, statins remain underutilized in this population, highlighting the need for increased awareness and adherence to clinical guidelines.